

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JC108  
2 2004  
TRADEMARK OFFICE

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/207,655		
		Filing Date	7/25/02		
		First Named Inventor	Ledbetter		
		Group Art Unit	1642		
		Examiner Name	Helms		
Sheet	1	of	13	Attorney Docket Number	49076.000004.CIP1

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
LAB	A.	4,704,692		Ladner	11/03/87
	B.	4,816,567		Cabilly et al.	03/28/89
	C.	4,906,562		Hellstrom et al	03/06/90
	D.	4,935,495		Hellstrom et a	06/19/90
	E.	4,946,778		Ladner et al.	08/07/90
	F.	5,091,177		Hellstrom et al	02/25/92
	G.	5,098,833		LASKY et al.	03/24/92
	H.	5,225,539		Winter	07/06/93
	I.	5,260,203		LADNER et al.	11/09/93
	J.	5,434,131		LINSLEY et al.	07/18/95
	K.	5,455,030		LADNER et al.	10/03/95
	L.	5,500,362		Robinson et al	03/19/96
	M.	5,521,288		LINSLEY et al.	05/28/96
	N.	5,530,101		Queen et al	06/25/96
	O.	5,580,756		LINSLEY et al.	12/03/96
	P.	5,585,089		Queen et al.	12/17/96
	Q.	5,597,707		Marken et al.	01/28/97
	R.	5,605,690		JACOBS et al.	02/25/97
	S.	5,637,481		LEDBETTER et al.	06/10/97
	T.	5,645,835		Fell, Jr. et al.	07/08/97
	U.	5,693,762		Queen et al.	12/02/97
	V.	5,709,859		ARUFFO et al.	01/20/98
	W.	5,714,147		CAPON et al.	02/03/98
	X.	5,770,197		LINSLEY et al.	06/23/98
	Y.	5,773,253		LINSLEY et al.	06/30/98
	Z.	5,795,572		Diegel et al.	08/18/98
	AA.	5,807,734		Diegel et al.	09/15/98
✓	BB.	5,844,095		LINSLEY et al.	12/01/98

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------


Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/207,655
Filing Date	7/25/02
First Named Inventor	Ledbetter
Group Art Unit	1642
Examiner Name	Helms
Attorney Docket Number	49076.000004.CIP1

Sheet 2 of 13

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
LAG	CC.	5,869,049		NOELLE et al.	02/9/99
	DD.	5,869,620		Whitlow et al.	02/09/99
	EE.	5,876,718		NOELLE et al.	03/02/99
	FF.	5,876,950		Siadak et al.	03/02/99
	GG.	5,888,773		Jost et al.	03/30/99
	HH.	5,892,019		Schlom et al.	04/06/99
	II.	5,916,560		LARSEN et al.	06/29/99
	JJ.	6,087,329		ARMITAGE et al.	07/11/00
	KK.	6,090,914		LINSLEY et al.	07/18/00
	LL.	6,015,695		Casterman et al.	01/18/00
	MM.	6,194,551 B1		IDUSOGIE et al.	02/27/01
	NN.	6,264,951 B1		ARMITAGE et al.	07/24/01
	OO.	6,312,692 B1		NOELLE et al.	11/06/01
	PP.	6,376,459 B1		ARUFFO et al.	04/23/02
	QQ.	6,384,198 B1		DIEGEL et al.	05/07/02
	RR.	6,410,319 B1		RAUBITSCHKE et al.	06/25/02
	SS.	6,444,792 B1		GRAY et al.	09/03/02
	TT.	6,472,510 B1		ARUFFO et al.	10/29/02
	UU.	6,623,940 B1		LEDBETTER et al.	09/23/03
	VV.	6,641,809 B1		LINSLEY et al.	11/04/03
	WW.	2003/0088074		Hamers et al.	05/08/03
	XX.	2003/0219876 A1		LEDBETTER et al.	11/27/03
	YY.	2003/0219446 A1		LINSLEY et al.	11/27/03
	ZZ.	2003/0219436 A1		LEDBETTER et al.	11/27/03
	AAA.	2002/0155604 A1		LEDBETTER et al.	10/24/02
	BBB.	2004/0058445 A1		LEDBETTER et al.	03/25/04
	CCC.	2002/0039557 A1		WHITE	04/04/02
	DDD.	2002/0031510 A1		LARSEN et al.	03/14/02
✓	EEE.	2001/004135 A1		STAHL et al.	11/22/01


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete If Known</b>		
				Application Number		10/207,655
				Filing Date		7/25/02
				First Named Inventor		Ledbetter
				Group Art Unit		1642
				Examiner Name		Helms
Sheet	3	of	13	Attorney Docket Number		49076.000004.CIP1

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	
		Office <sup>3</sup>	Kind Code <sup>5</sup> Number <sup>4</sup> (if known)				
LAB	FFF.	WO	89/07142		Morrison et al	08/10/89	
	GGG.	WO	92/00092		BRISTOL-MYERS SQUIBB COMPANY	01/09/92	
	HHH.	WO	93/00431		BRISTOL-MYERS SQUIBB COMPANY	01/07/93	
	III.	WO	94/04678		Casterman et al	03/03/94	
	JJJ.	WO	94/25591		Hamers et al	11/10/94	
	KKK.	WO	96/34103		Hamers et al	10/31/96	
	LLL.	WO	99/42077		XCYTE THERAPIES INC.	08/26/99	
	MMM.	EP	0 555 880 A2		BRISTOL-MYERS SQUIBB COMPANY	08/18/93	
	NNN.	EP	0 757 099 A2		BRISTOL-MYERS SQUIBB COMPANY	07/21/95	
	OOO.	EP	0 682 039 A1		BRISTOL-MYERS SQUIBB COMPANY	11/15/95	
	PPP.	EP	1 186 300 A1		BRISTOL-MYERS SQUIBB COMPANY	03/13/02	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>			
		Application Number	10/207,655		
		Filing Date	7/25/02		
		First Named Inventor	Ledbetter		
		Group Art Unit	1642		
		Examiner Name	Helms		
Sheet	4	of	13	Attorney Docket Number	49076.000004.CIP1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LAB	QQQ.	AICHER, et al., "Characterization of Human Inducible Costimulator Ligand Expression and Function", The Journal of Immunology, 2000, 164: 4689-4696	
	RRR.	Batra et al., "Single-Chain Immunotoxins at the Human Transferrin Receptor Containing Pseudomonas Exotoxin A or Diphtheria Toxin: Anti-TFR(Fv)-PE40 and DT388-Anti-TFR(Fv)," Molecular and Cellular Biology; 11(4):2200-2205, April 1991.	
	SSS.	Beiske et al., "Triggering of Neoplastic B Cells Via Surface IgM and the Cell Surface Antigens CD20 and CDw40. Responses Differ from Normal Blood B Cells and are Restricted to Certain Morphologic Subsets," Int. J. Cancer 42:521-528, 1988.	
	TTT.	BREKKE et al., "The Structural Requirements for Complement Activation by IgG: Does It Hinge on the Hinge?", Immunol. Today 16:85-90 (1995)	
	UUU.	Brown et al., "Treatment of B-Cell Lymphomas With Anti-idiotypic Antibodies Alone and in Combination With Alpha Interferon," Blood 73(3):651-661, February 15, 1989.	
	VVV.	BURKE et al., "Radioimmunotherapy for Acute Leukemia", Cancer Control, 9:106-113 (2002)	
	WWW.	CARTER, "Improving the Efficacy of Antibody-Based Cancer", Nature, November 2001, Volume 1, 118-129	
	XXX.	Chaudhary et al., "A recombinant immunotoxin consisting of two antibody variable domains, fused to Pseudomonas exotoxin," Nature 339:394-397, June 1, 1989.	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>			
		Application Number	10/207,655		
		Filing Date	7/25/02		
		First Named Inventor	Ledbetter		
		Group Art Unit	1642		
		Examiner Name	Helms		
Sheet	5	of	13	Attorney Docket Number	49076.000004.CIP1

LAB	YYY.	Clark et al., "Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50," Proc. Natl. Acad. Sci. USA 83:4494-4498, June 1986.	
	ZZZ.	CLARK et al., "Structure, Function, and Genetics of Human B Cell-Associated Surface Molecules", Advances in Cancer Research, Vol. 52, 81-149	
	AAAA.	COLOMA, et al., "The Hinge as a Spacer Contributes to Covalent Assembly and Is Required for Function of IgG", J. Immunol. 158(2):733-40	
	BBBB.	<del>DAMLE, et al., "Direct helper T cell induced B cell differentiation involves interaction between T cell antigen CD28 and B cell activation antigen B7"</del>	
LAB	CCCC.	DAVIES, et al., "Camelising' Human Antibody Fragments: NMR Studies on VH Domains," FEBS Letters 339 (1994) 285-290	
	DDDD.	Davis et al., High Level Expression in Chinese Hamster Ovary Cells of Soluble Forms of CD4 T Lymphocyte Glycoprotein Including Glycosylation Variants," The Journal of Biological Chemistry 265(18):10410-10418, June 25, 1990.	
	EEEE.	DESMYTER et al., "Crystal structure of a camel single-domain V <sub>H</sub> antibody fragment in complex with lysozyme", Nature Structural Biology, Volume 3, Number 9, September 1996, 803-811	
	FFFF.	DIETSCH et al., "Bispecific receptor globulins, novel tools for the study of cellular interactions", Journal of Immunological Methods, 162 (1993) 123-132	
	GGGG.	DIETSCH et al., "Coengagement of CD2 with LFA-1 or VLA-4 by bispecific ligand fusion proteins primes T cells to respond more effectively to T cell receptor-dependent signals, Journal of Leukocyte Biology, Volume 56, October 1994, 444-452	
	HHHH.	Dillman et al., "Continuous Infusion of T 101 Monoclonal Antibody in Chronic Lymphocytic Leukemia and Cutaneous T-Cell Lymphoma, Journal of Biological Response Modifiers 5(5):394-410, 1986.	
	IIII.	DORAI, et al., "Role of InteFHeavy and Light Chain Disulfide Bonds in the Effector Functions of Human Immunoglobulin IgG1", MoL Immunology 29:1487-1491 (1992).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>			
		Application Number	10/207,655		
		Filing Date	7/25/02		
		First Named Inventor	Ledbetter		
		Group Art Unit	1642		
		Examiner Name	Helms		
Sheet	6	of	13	Attorney Docket Number	49076.000004.CIP1

LAD	JJJJ.	DUNCAN, et al., "The Binding Site for Clq on IgG", Nature, 322:738-740 (1988)	
	KKKK.	DURIE et al., "Prevention of Collagen-Induced Arthritis with an Antibody to gp39, the Ligand for CD40", Science, Vol. 261, September 3, 1993, 1328-1330	
	LLLL.	Einfeld et al., "Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains," EMBO Journal 7:711-717, 1988.	
	MMMM.	FELL et al., "Genetic Construction and Characterization of a Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2", The Journal of Immunology, Vol. 146, 2446-2452, No. 7, April 1, 1991	
	NNNN.	FILPULA et al., "Single-chain Fv designs for protein, cell and gene therapeutics" Exp. Opin. Ther. Patents (1999) 9 (3):231-245	
	OOOO.	Funakoshi et al., "Differential In Vitro and In Vivo Antitumor Effects Mediated by Anti CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lymphomas," Journal of Immunotherapy 19(2):93-101, 1996.	
	PPPP.	Funakoshi et al., "Inhibition of Human B-Cell Lymphoma Growth by CD40 Stimulation," Blood 83(10):2787-2794, May 15, 1994.	
	QQQQ.	Genbank Accession No. L07414, April 27, 1993.	
	RRRR.	Genbank Accession No. M62541, July 26, 1993.	
	SSSS.	Genbank Accession No. M62542, April 27, 1993.	
	TTTT.	Genbank Accession No. M83312, September 23, 1996.	
✓	UUUU.	Genbank Accession No. M84371, July 17, 1995.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

Please type a plus sign (+) inside this box

JUL 02 2004

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/207,655		
		Filing Date	7/25/02		
		First Named Inventor	Ledbetter		
		Group Art Unit	1642		
		Examiner Name	Helms		
Sheet	7	of	13	Attorney Docket Number	49076.000004.CIP1

LAB	VVVV.	Genbank Accession No. U15637, March 8, 2002.	
	WWWW.	Genbank Accession No. X14046, September 12, 1993.	
	XXXX.	Genbank Accession No. X53517, February 17, 1992.	
	YYYY.	Genbank Accession No. X65453, April 26, 2001.	
	ZZZZ.	Genbank Accession No. X67878, June 6, 1997.	
	AAAAA.	Genbank Accession No. X96710, February 13, 1997.	
	BBBBB.	Genbank Accession No. Y10507, September 4, 1997.	
	CCCCC.	GILLIES, et al., "Antigen Binding and Biological Activities of Engineered Mutant Chimeric Antibodies with Human Tumor Specificities", Hum. Antibodies Hybridomas 1:47-54 (1990)	
	DDDDD.	GILLILAND et al., "Rapid and Reliable Cloning of antibody Variable Regions and Generation of Recombinant Single Chain Antibody Fragments", Tissue Antigens 1996: 47: 1-20 (Denmark0	
	EEEEE.	Hamers-Casterman et al., Naturally occurring antibodies devoid of light chains. Nature. 1993 Jun 3;363(6428):446-8.	
	FFFFF.	HAYDEN et al., "Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen", Tissue Antigens 1996: 48; 242-254	
	GGGGG.	HAYDEN, et al., "Antibody Engineering," Curr. Opin. Immuno., 9:201-212 (1997)	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/207,655
		Filing Date	7/25/02
		First Named Inventor	Ledbetter
		Group Art Unit	1642
		Examiner Name	Helms
Sheet 8 of 13	Attorney Docket Number		49076.000004.CIP1

LAB	HHHHH.	HAYDEN, et al., "Single-chain Mono- and bispecific Antibody Derivatives With Novel Biological Properties and Antitumor Activity from a COS Cell Transient Expression System," Thera. Immuno., 1:3-15 (1994)	
	IIIII.	HEKMAN et al., "Initial experience with treatment of human B cell lymphoma with anti CD19 monoclonal antibody," Cancer Immunol Immunother. 32:364-372, 1991.	
	JJJJJ.	HOLLENBAUGH et al., "The Human T cell antigen gp39, a member of the TNF gene family, is ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity," EMBO Journal 11:4313-4321, 1992.	
	KKKKK.	HU, et al., "Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-CH3) Which Exhibits Rapid, High-Level Targeting of Xenografts," Cancer Res. 56(13):3055-3061 (1996) (abstract only)	
	LLLLL.	HUDSON, "Recombinant antibodies: a novel approach to cancer diagnosis and therapy", Exp. Opin. Invest. Drugs (2000) 9(6):1231-1242	
	MMMMM.	HUDSON, "Recombinant antibody fragments", Current Opinion in Biotechnology, 1998, 9:395-402	
	NNNNN.	HUSTON et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxigenin single-chain Fv analogue produced in Escherichia coli," Proc. Natl. Acad. Sci. USA 85:5879-5883, August 1988.	
	OOOOO.	ISENMAN, et al., "Correlation between the Exposure of Aromatic Chromophores", Biochemistry 16:233-240 (1977)	
	PPPPP.	JOST et al., "Mammalian Expression and Secretion of Functional Single-chain Fv Molecules," The Journal of Biological Chemistry 269(42):26267-26273, October 21, 1994.	
	QQQQQ.	KAMINSKI et al., Radioimmunotherapy of B-Cell Lymphoma with [131] I Anti-B1 (Anti-CD20) Antibody, The New England Journal of Medicine 329(7):459-465, August 12, 1993	
	RRRRR.	KATO et al., "A conformational change in the Fc precludes the binding of two Fcy receptor molecules to one IgG," Immunol Today 21(7):310-312, July 2000.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/207,655		
		Filing Date	7/25/02		
		First Named Inventor	Ledbetter		
		Group Art Unit	1642		
		Examiner Name	Helms		
Sheet	9	of	13	Attorney Docket Number	49076.000004.CIP1

LAB	SSSSS.	KLEIN, et al., "Expression of Biological Effector Functions by Immunoglobulin G Molecules Lacking the Hinge Region", Proc. Natl. Acad. Sci. USA 78:524-528 (1981)	
	TTTTT.	KOOLWIJK et al., "Interaction Between Hybrid Mouse Monoclonal Antibodies and the Human High-Affinity IgG FcR, huFcTRI, on U937," The Journal of Immunology 143(5):1656-1662 1989.	
	UUUUU.	KORTT, et al., "Dimeric and Trimeric Antibodies: High Avidity scFvs for Cancer Targeting," Biomole. Eng., 18:95-108 (2001)	
	VVVVV.	LASVELD et al., Treatment of low-grade non-Hodgkin s lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD 19," Cancer Immunol. Immunother: 40:37-47, 1995.	
	WWWWW.	LEDBETTER et al., "Augmentation of Normal and Malignant B Cell Proliferation by Monoclonal Antibody to the B Cell-Specific Antigen BP50 (CDW40)," The Journal of Immunology 138(3):788-794, February 1, 1987.	
	XXXXX.	LEE et al., "Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions", Molecular Immunology 36 (1999) 61-71	
	YYYYY.	LI, et al., "Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification and effect on tumor growth", Cancer Immunol. Immunother (2000) 49:243-252	
	ZZZZZ.	LIU et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity," The Journal of Immunology 139(10):3521-3526, November 15, 1987.	
	AAAAAA.	LIU, et al., "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 With Potent Fc-Dependent Biological Activity," J. Immunol. 139(10):3521-3526 (1987)	
	BBBBBB.	MALONEY et al., "IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma," Blood 90(6):2188-2195, September 15, 1997.	
J	CCCCCC.	MALONEY et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients With Relapsed Non-Hodgkin's Lymphoma, Journal of Clinical Oncology 15(10):3266-3274, October 1997.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

Please type a plus sign (+) inside this box →

JUL 0 2 2004

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/207,655		
		Filing Date	7/25/02		
		First Named Inventor	Ledbetter		
		Group Art Unit	1642		
		Examiner Name	Helms		
Sheet	10	of	13	Attorney Docket Number	49076.000004.CIP1

LAB	DDDDDD.	MCLAUGHLIN et al., "IDEC-C2B8 ANTI-CD20 Antibody: Final Report on a Phase III Pivotal Trial in Patients (PTS) With Relapsed Low-Grade or Follicular Lymphoma (LG/F NHL)," Blood 88(Abstract Suppl. 1):90a, Abstract 349, 1996.	
	EEEEEE.	MICHAELSEN, et al., "Antibody Dependent Cell-Mediated Cytotoxicity Induced by Chimeric Mouse-Human IgG Subclasses ...", Mol Immunol. 29:319-326 (1992)	
	FFFFFF.	MICHAELSEN, et al., "Enhancement of Complement Activation and Cytolysis of " Human IgG3 by Deletion of Hinge Exons"; Scand. J Immunol. 32:517-528; 1990.	
	GGGGGG.	MICHAELSEN, et al., "One Disulfide Bond in Front of the Second Heavy Chain Constant Region...", Proc. Natl. Acad. Sci. USA 91:9243-9247 (1994).	
	HHHHHH.	MULTANI et al., "Monoclonal Antibody-Based Therapeis for Hematologic Malignancies", Journal of Clinical Oncology, Vol. 16, No 11 (November), 1998: pp 3691-3710	
	IIIIII.	NIKULA, et al., "Impact of the High Tyrosine Fraction in Complementarity I Determining Regions: ...", Mol. Immunol. 32:865-872 (1995)	
	JJJJJJ.	PARK et al., "Generation and Characterization of a Novel Tetravalent Bispecific antibody that binds to hepatitis B virus surface antigens", Molecular Immunology 37 (2000) 11-23-1130	
	KKKKKK.	PAWSON et al., "Treatment of T-Cell Prolymphocytic Leukemia With Human CD52 Antibody," Journal of Clinical Oncology 15(7):2667-2672, July 1997.	
	LLLLLL.	PRESS et al., " Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." N Engl J Med. 1993 Oct 21;329(17):1219-24.	
	MMMMMM.	PRESS et al., "Monoclonal Antibody 1 F5 (Anti-CD20) Serotherapy of Human B Cell Lymphomas," Blood 69(2):584-591, February 1987.	
	NNNNNN.	RADAEV AND SUN, "Recognition of IgG by Fc <sub>γ</sub> Receptor," The Journal of Biological Chemistry 276(19):16478-16483, May 11, 2001.	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/207,655
		Filing Date	7/25/02
		First Named Inventor	Ledbetter
		Group Art Unit	1642
		Examiner Name	Helms
Sheet 11 of 13	Attorney Docket Number	49076.000004.CIP1	

4103	OOOOOO.	RADAEV et al., "The Structure of a Human Type III FcT Receptor in Complex with Fc," The Journal of Biological Chemistry 276(19): 16469-16477, May 11, 2001.	
	PPPPPP.	REDPATH, et al., "The Influence of the Hinge Region Length in Binding of Human IgG to Human Fcγ Receptors", Hum. Immunol. 59:720-727 (1998)	
	QQQQQQ.	SCHEINBERG et al., "A Phase I Toxicity, Pharmacology, and Dosimetry Trial of Monoclonal Antibody OKB7 in Patients With Non-Hodgkin's Lymphoma: Effects of Tumor Burden and Antigen Expression," Journal of Clinical Oncology 8(5):792-803, May 1990.	
	RRRRRR.	SEGAL et al., "Introduction: bispecific antibodies", Journal of Immunological Methods, 248 (2001) 1-6	
	SSSSSS.	SENSEL et al., "Engineering Novel Antibody Molecules," Chemical Immunology 65:129-158 1997.	
	TTTTTT.	SHAN et al., "Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies," Blood 91(5):1644-1652, March 1, 1998.	
	UUUUUU.	SHAN et al., "Characterization of scFv-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths," The Journal of Immunology 162(11):6589- 6595, June 1, 1999.	
	VVVVVV.	SHIN et al., "Genetically-Engineered Antibodies: Tools for the Study of Diverse Properties of the Antibody Molecule," Immunological Reviews 130:87-107, 1992.	
	WWWWWW.	SHIN et al., "Hybrid Antibodies," Intern. Rev. ImmunoL 10:177-186, 1993.	
	XXXXXX.	SHU et al., "Secretion of a single-gene-encoded immunoglobulin from myeloma cells", Proc. Natl. Acad. Sci. USA, Vol. 90, 7995-7999, September 1993	
	YYYYYY.	SPELLIE, et al., "Radioimmunotherapy of Breast Cancer Xenografts with Monoclonal Antibody ICR12 ...", Cancer Res. 55:5842s-5846s (1995)	
✓	ZZZZZZ.	SONDERMANN et al., " The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gamma RIII complex. Nature. 2000 Jul 20;406(6793):267-73.	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/207,655		
		Filing Date	7/25/02		
		First Named Inventor	Ledbetter		
		Group Art Unit	1642		
		Examiner Name	Helms		
Sheet	12	of	13	Attorney Docket Number	49076.000004.CIP1

LAB	AAAAAAA.	SOURIAU et al., "Recombinant antibodies for cancer diagnosis and therapy", Expert Opin. Biol. Ther. (2003) 3(2):305-318	
	BBBBBBB.	SPORICI et al., "ICOS Ligand Costimulation Is Required for T-Cell Encephalitogenicity", Clinical Immunology, Vol. 100, No. 3, September, pp. 277-288, 2001	
	CCCCCCC.	TAN, et al, "Influence of the Hinge Region on Complement Activation, Clq Binding, and Segmental Flexibility in Chimeric Human Immunoglobulins", PNAS, USA, 87(1):162-6	
	DDDDDDD.	TAO, et al., "Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region", 1989, J. Immunol 143(8):2595-601	
	EEEEEEE.	THOMMESEN, et al., "Lysine 322 in the Human IgG3 CH2 Domain Is Crucial for Antibody Dependent Complement Activation", Mol Immunol, 37:995-1004 (2000)	
	FFFFFFF.	TRAUNECKER et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocyte on HIV infected cells," EMBO Journal 10:3655-3659, 1991.	
	GGGGGGG.	VAN DEN ABEELE, et al., "Antigen-Binding Site Protection During Radiolabeling Leads to a Higher Immunoreactive Fraction", J. Nucl. Med. 32:116-122 (1991)	
	HHHHHHH.	WALKER, et al., "Aglycosylation of Human IgG1 and IgG3 Monoclonal Antibodies Can Eliminate Recognition by Human Cells ...", 1989, Biochem. J. 259(2):347-53)	
	IIIIIII.	WHITE et al., Activation of dense human tonsillar B cells. Induction of c-myc gene expression via two distinct signal transduction pathways. J Immunol. 1991 Feb 1;146(3):846-53..	
	JJJJJJJ.	WU, et al., "Multimerization of a Chimeric Anti-CD20 Single-chain Fv-Fc Fusion Protein is Mediated Through Variable Domain Exchange," Protein Eng., 14(12):1025-1033 (2001)	
↓	KKKKKKK.	Ye z. et al; "Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med. 2002 Apr;8(4):343-8.	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/207,655		
		Filing Date	7/25/02		
		First Named Inventor	Ledbetter		
		Group Art Unit	1642		
		Examiner Name	Helms		
Sheet	13	of	13	Attorney Docket Number	49076.000004.CIP1


LAB	LLLLLLL.	YOKOTA et al "Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms" Cancer Res. 1992 52: 3402-3408.	
↓	MMMMMMM.	ZHOROV, et al., "Oxidative Iodination of Rabbit IgG: Localization of the Label in the Fc Fragment and Modification Effects", Biokhimiia 56:828-838 (1991)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document by the two-letter code (WPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of 2

**Complete if Known**

Application Number	10/627,556
Filing Date	July 26, 2003
First Named Inventor	LEDBETTER
Art Unit	1642
Examiner Name	HELMS, LARRY R.
Attorney Docket Number	49076-000004.CIP2

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
LAB		US- 5844093	12-01-1998	MERCK PATENT GMBH (D	
		US- 5736137	04-07-1998	RASTETTER W. et al	
		US- 5776456	07-07-1998	RASTETTER W. et al	
		US- 20030133930	07-17-2003	Goldenberg et al.	
		US- 2003-0219433	02-14-2003	Hansen H.	
		US- USSN 09/590,284	06-09-2000	Goldenberg et al.	
		US- 6147203	11-14-2000	Pastan et al.	
		US- 6074644	06-13-2000	Pastan et al.	
		US- 5677425	10-14-1977	Bodmer et al.	
		US- 6482919	11-19-2002	Ledbetter et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
LAB		WO0044777	08-03-2000	IMCLONE SYSTEMS		
		WO9221755	12-10-1992	GENENTECH INC		
		EP0586002	03-09-1994	Macineira et al		
		WO9509917	04-01-1995	COLOMA et al.		
		WO9405690	03-17-1994	Gross et al.		

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/627,556
Filing Date	July 26, 2003
First Named Inventor	LEDBETTER
Art Unit	1642
Examiner Name	HELMS, LARRY R
Attorney Docket Number	49076-000004.CIP2

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LAB		Munoz E. et The C(H)1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3. Int Immunol. 1998 Feb;10(2):97-106.	
		Martin S. et al., Efficient neutralization and disruption of rhinovirus by chimeric ICAM- 1/immunoglobulin molecules , J. Virol. 1993;67:3561-3568	
		Stevenson G.T. et al., Mechanisms in removal of tumor by antibody. Cell Biophys. 1994;24-25:45-50.	
		Anderson et al., Targeted anti-cancer therapy using rituximab, a chimeric anti-CD-20 antibody (IDEC-c2B8) in the treatment of non-hodgkin's B-cell lymphoma; Biochemical Society Transactions Colcester, Essex, GB, pg 705-708; 1997	

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

## Complete if Known

Application Number	10/627,556
Filing Date	July 26, 2003
First Named Inventor	Ledbetter et al.
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	49076.000004.CIP2

## U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
LAB ↓		US- 6,150,584 A	11-21-2000	Kucheralapati et al.	
		US- 6,284,536 B1	09-04-2001	Morrison et al.	
		US- 2003/0044423 A1	03-06-2003	Gillies et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

Examiner  
Signature

/Lynn Bristol/

Date  
Considered


11/05/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.





PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/627,556
Filing Date	July 26, 2003
First Named Inventor	Ledbetter et al.
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	49076.000004.CIP2

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LAD		CRUSE et al., "Illustrated Dictionary of Immunology", CRC Press, 1995, p. 157	
		PAUL, "Fundamental Immunology", Raven Press, 1993, Chp. 8, p. 242	
		RUDIHOFF et al., "Single amino acid substitution altering antigen-binding specificity", Proc Natl Acad Sci U S A, 1982 March, 79(6):1979-83	

Examiner Signature	/Lynn Bristol/	Date Considered	11/05/2006
-----------------------	----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.